Cat. #152434
SW1222 Cell Line
Cat. #: 152434
Unit size: 1x10^6 cells / vial
Organism: Human
Tissue: Colon
Disease: Cancer
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Walter Bodmer
Institute: University of Oxford
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: SW1222 Cell Line
- Alternate name: SW-1222; SW 1222
- Cancer type: Colorectal cancer
- Cancers detailed: Human colorectal adenocarcinoma
- Research fields: Cancer;Drug development
- Organism: Human
- Tissue: Colon
- Disease: Cancer
- Growth properties: Growth mode: adherent
- Conditional: Yes
- Description: The SW1222 cell line was established from a patient with a moderately well differentiated adenocarcinoma of the colon classified as Dukes' stage C. SW1222 cells produce tumours in female athymic nu/nu nude mice. This cell line carries hallmark mutations including APC, TP53, and KRAS. In 3D matrices, SW1222 forms crypt-like glands and lumen-containing structures, mimicking human colon architecture. It is a widely for studying Wnt/β-catenin signalling, cancer stem cells and colon-like differentiation patterns.
- Additional notes: STR-PCR Data: Amelogenin: X,Y CSF1PO: 11 D13S317: 9,13 D16S539: 9,10 D5S818: 9 D7S820: 10,12 THO1: 7 TPOX: 10 vWA: 18
- Cellosaurus id: CVCL_3886
Applications
- Application notes: STR-PCR Data: Amelogenin: X,Y CSF1PO: 11 D13S317: 9,13 D16S539: 9,10 D5S818: 9 D7S820: 10,12 THO1: 7 TPOX: 10 vWA: 18
Handling
- Format: Frozen
- Growth medium: Iscove's Modified Dulbecco's Medium, + 10% Foetal Bovine Serum (FBS) + 2 mM Glutamine
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
- Subculture routine: Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 2-4x10,000 cells/cm² using 0.05% trypsin or trypsin/EDTA; 5% CO₂; 37°C.
References
- Rinne et al. 2025. Theranostics. 15(15):7489-7500. PMID: 40756357.
- Shaala et al. 2025. Mar Drugs. 23(7):262. PMID: 40710487.
- Perez-Pedroza et al. 2024. J Vis Exp. PMID: 38767378.
- Vaughn et al. 2024. J Nucl Med. 65(10):1611-1618. PMID: 39168519.
- Delaney et al. 2023. Mol Imaging Biol. 25(6):1104-1114. PMID: 37052759.
- Abdelrahman et al. 2021. Molecules. 26(16):4730. PMID: 34443319.
- Bacac et al. 2016. Clin Cancer Res. 22(13):3286-3297. PMID: 26861458.
- Hsia et al. 2016. Proc Natl Acad Sci U S A. 113(15):E2162-2171.PMID: 27036009.
- Yeung et al. 2010. Proc Natl Acad Sci U S A. 107(8):3722-3727. PMID: 20133591.
- Efstathiou et al. 1999. Proc Natl Acad Sci U S A. 96(5):2316-2321. PMID: 10051639.
- Browning et al. 1993. J Immunother Emphasis Tumor Immunol. 14(3):163-168. PMID: 8297898.
- Richman et al. 1988. J Pathol. 156(3):197-211. PMID: 3204451.
